Type-2 diabetes mellitus and cardiovascular disease

Papers of special note have been highlighted as: • of interest

References

• 1 Global Report on Diabetes. World Health Organization. Diabetes Fact Sheet, ISBN 978 92 4 156525 7 (NLM classification: WK 810) (2016). https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=69071D7B7A452E8DF854B6A40?sequen. • WHO information regarding global problem of diabetes mellitus.
  Google Scholar
• 2 Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res. Clin. Pract. 103(2), 150–160 (2014).
  MedlineGoogle Scholar
• 3 Gakidou E, Mallinger L, Abbott-Klafter J et al. Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys. Bull. World Health Organ. 89(3), 172–183 (2011).
  MedlineGoogle Scholar
• 4 Noncommunicable Disease Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387(10027), 1513–1530 (2016).
  MedlineGoogle Scholar
• 5 Bloom D, Cafiero E, Jané-Llopis E et al. The global economic burden of noncommunicable diseases (Working Paper Series). Presented at: Harvard School of Public Health and World Economic Forum. Geneva, Switzerland, 19–20 September 2011.
  Google Scholar
• 6 Dabelea D. The accelerating epidemic of childhood diabetes. Lancet 373(9680), 1999–2000 (2009).
  MedlineGoogle Scholar
• 7 Imamura F, O'Connor L, Ye Z et al. Consumption of sugar-sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ 351, h3576 (2015).
  MedlineGoogle Scholar
• 8 Turner R, Millins H, Neil H et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) the United Kingdom Prospective Diabetes Study Group. BMJ 316, 823–828 (1998).
  Medline CASGoogle Scholar
• 9 Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375(9733), 2215–2222 (2010).
  Medline CASGoogle Scholar
• 10 Singh G, Danaei G, Farzadfar F et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS ONE 8(7), e65174 (2013).
  Medline CASGoogle Scholar
• 11 Danaei G, Lawes C, Vander HS, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 368(9548), 1651–1659 (2006).
  MedlineGoogle Scholar
• 12 Beckman J, Creager M, Libby P. Diabetes mellitus: epidemiology, pathophysiology, and management. JAMA 287(19), 2570–2581 (2002).
  Medline CASGoogle Scholar
• 13 Vazquez-Benitez G, Desai JR, Xu S et al. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. Diabetes Care 38(5), 905–912 (2015).
  Medline CASGoogle Scholar
• 14 Moe B, Eilertsen E, Nilsen T. The combined effect of leisure-time physical activity and diabetes on cardiovascular mortality: the Nord-Trondelag Health (HUNT) cohort study, Norway. Diabetes Care 36(3), 690–695 (2013).
  MedlineGoogle Scholar
• 15 Zoungas S, Woodward M, Li Q et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia 57(12), 2465–2474 (2014).
  MedlineGoogle Scholar
• 16 The Advance Cooperative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358(24), 2560–2572 (2008). • The Advance Cooperative Group trial on intensive blood glucose control.
  MedlineGoogle Scholar
• 17 Wackers F, Young L, Inzucchi S et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects. The DIAD study. Diabetes Care 27(8), 1954–1961 (2004). • The DIAD study on silent myocardial ischemia in patients with diabetes.
  MedlineGoogle Scholar
• 18 Sassoc F, Furbatto F, Carbonara O et al. Prevalence of diabetes in patients with nonacute CAD. Acta Diabetol. 48(3), 247–248 (2011).
  MedlineGoogle Scholar
• 19 McGinn J, Shariff M, Bhat T et al. Prevalence of dysglycemia among coronary artery bypass surgery patients with no previous diabetic history. J. Cardiothorac. Surg. 6, 104 (2011).
  MedlineGoogle Scholar
• 20 Turnbull F, Abraira C, Anderson R et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52(11), 2288–2298 (2009).
  Medline CASGoogle Scholar
• 21 Skyler J, Bergenstal R, Bonow R. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation 119(2), 351–357 (2009). • Review of ACCORD, ADVANCE and VA trials regarding intensive blood glucose control and cardiovascular complications.
  MedlineGoogle Scholar
• 22 Herman W, Ye W, Griffin S et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care 38(8), 1449–1455 (2015).
  MedlineGoogle Scholar
• 23 Inge T, King W, Jenkins T et al. The effect of obesity in adolescence on adult health status. Pediatrics 132, 1098–1104 (2013).
  MedlineGoogle Scholar
• 24 Hales C, Carroll M, Fryar C, Ogden C. Prevalence of obesity among adults and youth: United States, 2015–2016. National Center for Health Statistics Data Brief. 288, 1–8 (2017).
  Google Scholar
• 25 Sluik D, Boeing H, Montonen J et al. Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am. J. Epidemiol. 174, 22–34 (2011).
  MedlineGoogle Scholar
• 26 Whitlock G, Lewington S, Sherliker P et al. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373(9669), 1083–1096 (2009).
  MedlineGoogle Scholar
• 27 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317, 703–713 (1998).
  MedlineGoogle Scholar
• 28 The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010). • The ACCORD study on intensive blood pressure control in patients with diabetes.
  MedlineGoogle Scholar
• 29 Leon B, Maddox T. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diabetes 6(13), 1246–1258 (2015).
  MedlineGoogle Scholar
• 30 Whelton P, Carey R, Aronow W et al. CC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J. Am. Coll. Cardiol. 71(19), e127 (2017).
  MedlineGoogle Scholar
• 31 Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2013).
  Google Scholar
• 32 Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
  Medline CASGoogle Scholar
• 33 Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374), 2005–2016 (2003).
  MedlineGoogle Scholar
• 34 Kearney PM, Blackwell L, Collins R et al. Cholesterol Treatment Trialists’ collaborators, efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607), 117–125 (2008). • Effects of cholesterol reduction in patients with diabetes.
  Medline CASGoogle Scholar
• 35 Colhoun H, Betteridge D, Durrington P et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364(9435), 685–696 (2004).
  Medline CASGoogle Scholar
• 36 Sattar N, Preiss D, Murray H et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735–742 (2010).
  Medline CASGoogle Scholar
• 37 Olafsdottir E, Aspelund T, Sigurdsson G et al. Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik study. BMJ Open 1(1), e000132 (2011).
  MedlineGoogle Scholar
• 38 Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298(22), 2654–2664 (2007).
  Medline CASGoogle Scholar
• 39 Jankowich M, Choudhary G, Taveira T, Wu W-C. Age-, race-, and gender-specific prevalence of diabetes among smokers. Diabetes Res. Clin. Pract. 93, e101–e105 (2011).
  MedlineGoogle Scholar
• 40 Cowie C, Rust K, Byrd-Holt D et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care 33(3), 562–568 (2010).
  MedlineGoogle Scholar
• 41 Herman W, Kalyani R, Cherrington A. American diabetes association standards of medical care in diabetes. Diabetes Care 40(Suppl. 1), S1–S132 (2017). • American Diabetes Association guidelines for the treatment of diabetes mellitus.
  MedlineGoogle Scholar
• 42 Rask-Madsen C, King G. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 17(1), 20–33 (2013).
  Medline CASGoogle Scholar
• 43 Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr. Atheroscler. Rep. 2(5), 430–436 (2000).
  Medline CASGoogle Scholar
• 44 Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350(7), 664–671 (2004).
  Medline CASGoogle Scholar
• 45 Creager M, Luscher T, Cosentino F, Beckman J. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108(12), 1527–1532 (2003).
  MedlineGoogle Scholar
• 46 Kim JK. Endothelial nuclear factor kappa B in obesity and aging: Is endothelial nuclear factor kappa B a master regulator of inflammation and insulin resistance? Circulation 125(9), 1081–1083 (2012).
  MedlineGoogle Scholar
• 47 Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2) homeostasis in diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 280(4), H1480–H1489 (2001).
  Medline CASGoogle Scholar
• 48 Trayhurn P, Wood IS. Signaling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 33(Pt 5), 1078–1081 (2005).
  Medline CASGoogle Scholar
• 49 Rosenson RS. Clinical role of LDL and HDL subclasses and apolipoprotein measurement. ACC Curr. J. Rev. 13(5), 33–37 (2004).
  Google Scholar
• 50 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105(9), 1135–1143 (2002).
  Medline CASGoogle Scholar
• 51 Zampetaki A, Kiechl S, Drozdov I et al. Plasma microRNA profiling reveals loss of endothelial mir-126 and other microRNAs in type 2 diabetes. Circ. Res. 107(6), 810–817 (2010).
  Medline CASGoogle Scholar
• 52 Caporali A, Meloni M, Vollenkle C et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123(3), 282–291 (2011).
  Medline CASGoogle Scholar
• 53 Yahagi K, Kolodgie F, Lutter C et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 37(2), 191–204 (2017).
  Medline CASGoogle Scholar
• 54 Jensen M, Ryan D, Apovian C et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129, S102–S138 (2014). • Guidelines for the management of obesity.
  MedlineGoogle Scholar
• 55 Knowler WC, Barrett-Connor E, Fowler S et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393–403 (2002).
  Medline CASGoogle Scholar
• 56 Fox C, Golden S, Anderson C et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 132(8), 691–718 (2015).
  Medline CASGoogle Scholar
• 57 Sjöström L, Lindroos A, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351(26), 2683–2693 (2004).
  MedlineGoogle Scholar
• 58 Carlsson LM, Peltonen M, Ahlin S et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N. Engl. J. Med. 367(8), 695–704 (2012). • The Swedish study on the treatment of obesity with bariatric surgery.
  Medline CASGoogle Scholar
• 59 Clair C, Rigotti NA, Porneala B et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 309(10), 1014–1021 (2013).
  Medline CASGoogle Scholar
• 60 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903–1913 (2002).
  MedlineGoogle Scholar
• 61 Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 313(6), 603–615 (2015).
  MedlineGoogle Scholar
• 62 Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst. Rev. 10, CD008277 (2013).
  Google Scholar
• 63 Whelton P, Carey R, Aronow W et al. 2017 Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J. Am. Coll. Cardiol. 71(19), 2199–2269 (2018). • Joint National Commission hypertension guidelines.
  MedlineGoogle Scholar
• 64 Kirkman MS, Briscoe VJ, Clark N et al. Diabetes in older adults. Diabetes Care 35(12), 2650–2664 (2012).
  MedlineGoogle Scholar
• 65 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355(9200), 253–259 (2000).
  MedlineGoogle Scholar
• 66 Palmer S, Mavridis D, Navarese E et al. Comparative efficacy and safety of blood pressure lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385(9982), 2047–2056 (2015).
  Medline CASGoogle Scholar
• 67 Peters S, Huxley R, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57(8), 1542–1551 (2014).
  MedlineGoogle Scholar
• 68 Kalyani R, Lazo M, Ouyang P et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care 37(3), 830–838 (2014).
  MedlineGoogle Scholar
• 69 Bhatt DL, Bonaca M, Bansilal S et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J. Am. Coll. Cardiol. 67(23), 2732–2740 (2016).
  Medline CASGoogle Scholar
• 70 Defronzo RA. Banting lecture: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4), 773–795 (2009).
  Medline CASGoogle Scholar
• 71 Gerstein H, Miller M, Byington R et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358(24), 2545–2559 (2008).
  Medline CASGoogle Scholar
• 72 Qaseem A, Wilt T, Kansagara D et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann. Intern. Med. 168(8), 569–576 (2018). • 2018 Guidelines for treatment of Type 2 diabetes (T2D) from the American College of Physicians.
  MedlineGoogle Scholar
• 73 Madiraju AK, Erion DM, Rahimi Y et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510(7506), 542–546 (2014).
  Medline CASGoogle Scholar
• 74 Hong J, Zhang Y, Lai S et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36(5), 1304–1311 (2013).
  Medline CASGoogle Scholar
• 75 Lipska K, Bailey C, Inzucchi S. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34(6), 1431–1437 (2011).
  Medline CASGoogle Scholar
• 76 Inzucchi S, Bergenstal R, Buse J et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 35(6), 1364–1379 (2012).
  Medline CASGoogle Scholar
• 77 Inzucchi S. Personalizing glucose-lowering therapy in patients with type 2 diabetes and cardiovascular disease. Endocrinol. Metab. Clin. North Am. 47(1), 137–152 (2018). • Recommendations for glucose-lowering therapy.
  MedlineGoogle Scholar
• 78 Dormandy J, Charbonnel B, Eckland D et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events): a randomised controlled trial. Lancet 366(9493), 1279–1289 (2005).
  Medline CASGoogle Scholar
• 79 Nathan D, Buse J, Kahn S et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 36(8), 2254–2261 (2013).
  Medline CASGoogle Scholar
• 80 Marso S, Daniels G, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375(4), 311–322 (2016). • LEADER trial on the use of liraglutide in T2D.
  Medline CASGoogle Scholar
• 81 Inzucchi S, Bergenstal R, Buse J et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care 38(1), 140–149 (2015).
  MedlineGoogle Scholar
• 82 Zinman B, Wanner C, Lachin J et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128 (2015). • Sodium-glucose cotransporter-2 empagliflozin in the treatment of T2D.
  Medline CASGoogle Scholar
• 83 Neal B, Perkovic V, Mahaffey K et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644–657 (2017).
  Medline CASGoogle Scholar
• 84 Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 interim update. Can. J. Diabetes 40(3), 193–195 (2016).
  MedlineGoogle Scholar
• 85 Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363, 1410–1418 (2010).
  Medline CASGoogle Scholar
• 86 Holman R, Thorne K, Farmer A et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J. Med. 357, 1716–1730 (2007).
  Medline CASGoogle Scholar
• 87 Timmer J, Ottervanger J, de Boer M et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch. Intern. Med. 167(13), 1353–1359 (2007).
  MedlineGoogle Scholar
• 88 Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 346, 957 (2002).
  Medline CASGoogle Scholar
• 89 Kundu A, Sardar P, O'Day K. SYNTAX score and outcomes of coronary revascularization in diabetic patients. Curr. Cardiol. Rep. 20(5), 28 (2018).
  MedlineGoogle Scholar
• 90 Jiang Y-J, Han W-X, Gao C et al. Comparison of clinical outcomes after drug-eluting stent implantation in diabetic versus nondiabetic patients in China. A retrospective study. Medicine 96(17), e6647 (2017).
  Medline CASGoogle Scholar
• 91 Ledru F, Ducimetiere P, Battaglia S et al. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J. Am. Coll. Cardiol. 37(6), 1543–1550 (2001).
  Medline CASGoogle Scholar
• 92 Goraya T, Leibson C, Palumbo P et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J. Am. Coll. Cardiol. 40(5), 946–953 (2002).
  MedlineGoogle Scholar
• 93 Silva J, Escobar A, Collins TJ et al. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 92, 1731–1736 (1995).
  Medline CASGoogle Scholar
• 94 Cola C, Brugaletta S, Martin Yuste V et al. Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc. Health Risk Manag. 5(1), 101–119 (2009).
  MedlineGoogle Scholar
• 95 Kornowski R, Mintz G, Kent K et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 95(6), 1366–1369 (1997).
  Medline CASGoogle Scholar
• 96 The Bypass Angioplasty Revascularization Investigation (BARI). Influence of diabetes on 5-year mortality in a randomized trial comparing CAGB and PTCA in patients with multivessel disease. Circulation 96(6), 1761–1769 (1997).
  MedlineGoogle Scholar
• 97 Abizaid A, Costa MA, Centemero M et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularizations Therapy Study (ARTS) trial. Circulation 104(5), 533–538 (2001).
  Medline CASGoogle Scholar
• 98 Hueb W, Soares P, Gersh B. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J. Am. Coll. Cardiol. 43(10), 743–751 (2004).
  Google Scholar
• 99 Farkouh M, Domanski M, Sleeper L et al. Strategies for multivessel revascularization in patients with diabetes. N. Engl. J. Med. 367(25), 2375–2384 (2012).
  Medline CASGoogle Scholar
• 100 Habib R, Dimitrova K, Badour S et al. Greater benefit in long-term outcomes with multiple arterial bypass grafting. J. Am. Col. Cardiol. 66(13), 1417–1427 (2015). • Advantages of coronary artery bypass graft surgery in patients with multivessel disease.
  MedlineGoogle Scholar
• 101 Raza S, Blackstone E, Houghtaling P et al. Similar outcomes in diabetes patients after coronary artery bypass grafting with single internal thoracic artery plus radial artery grafting and bilateral internal thoracic artery grafting. Ann. Thorac. Surg. 104(6), 1923–1932 (2017).
  MedlineGoogle Scholar
• 102 Pevni D, Medalion B, Mohr R et al. Should bilateral internal thoracic artery grafting be used in patients with diabetes mellitus? Ann. Thorac. Surg. 103(2), 551–558 (2016).
  MedlineGoogle Scholar
• 103 McGrath B, Norris C, Hardwicke-Brown E et al. Quality of life following coronary artery bypass graft surgery vs. percutaneous coronary intervention in diabetics with multivessel disease: a five-year registry study. Eur. Heart J. Qual. Care Clin. Outcomes 3(3), 216–223 (2017).
  MedlineGoogle Scholar
• 104 Maggioni AP, Greene SJ, Fonarow GC et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur. Heart J. 34(40), 3117–3127 (2013).
  Medline CASGoogle Scholar
• 105 Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27(3), 699–703 (2004).
  MedlineGoogle Scholar
• 106 Greene S, Vaduganathan M, Khan M. Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes. J. Am. Coll. Cardiol. 71(12), 1379–1390 (2018).
  MedlineGoogle Scholar
• 107 Paulus W, Dal Canto E. Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction. J. Am. Coll. Cardiol. Heart Failure 6, 1–7 (2018).
  MedlineGoogle Scholar
• 108 Yancy C, Jessup M, Bozkurt B et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation 136, e137–e161 (2017).
  MedlineGoogle Scholar
• 109 Ponikowski P, Voors AA, Anker SD et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology. Eur. J. Heart Fail. 18(8), 891–975 (2016). • Guidelines for the treatment of patients with heart failure.
  MedlineGoogle Scholar
• 110 Bruni A, Gala-Lopez B, Pepper A et al. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab. Syndr. Obes. 7, 211–223 (2014).
  Medline CASGoogle Scholar
• 111 Voltarelli J, Couri C, Stracieri A et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297(14), 1568–1576 (2007).
  Medline CASGoogle Scholar